hit counter
Allakos Inc. (ALLK) Stock News Sentiment & Price - Sentifly
ALLK - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Allakos Inc. (ALLK)

USA
Biotechnology
NASDAQ
ALLK Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ALLK Latest news
GlobeNewsWire
Neutral
Allakos Provides Business Update and Reports Third Quarter 2021 Financial Results
2021-11-08 16:05

REDWOOD CITY, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2021.

GlobeNewsWire
Neutral
Allakos Presents Data at ACG 2021 from Prospective Study Showing High Prevalence Rates of Eosinophilic Gastritis and/or Eosinophilic Duodenitis with Systematic Evaluation
2021-10-25 08:00

– Study shows 45% (181/405) of patients with moderate-to-severe unexplained gastrointestinal symptoms who underwent upper endoscopy with biopsy met the histologic criteria for eosinophilic gastritis and/or eosinophilic duodenitis (EG/EoD) – – Presentation selected for “ACG Presidential Poster Award” –

GlobeNewsWire
Neutral
Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the American College of Gastroenterology 2021 Annual Scientific Meeting
2021-10-24 15:35

REDWOOD CITY, Calif., Oct. 24, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of six poster presentations at the upcoming American College of Gastroenterology (ACG) Annual Scientific Meeting.

The Motley Fool
Positive
3 Biotech Stocks With Huge Catalysts Incoming
2021-10-22 06:13

These drugmakers have big events that should occur before the end of 2021.

Zacks Investment Research
Positive
Implied Volatility Surging for Allakos (ALLK) Stock Options
2021-09-30 10:23

Investors need to pay close attention to Allakos (ALLK) stock based on the movements in the options market lately.

GlobeNewsWire
Neutral
Allakos Provides Business Update and Reports Second Quarter 2021 Financial Results
2021-08-09 16:01

REDWOOD CITY, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2021.

Seeking Alpha
Neutral
Allakos: Upcoming Phase 3 Data Makes The Stock Interesting
2021-08-06 06:39

ALLK is targeting a large and untapped market.

The Motley Fool
Positive
3 Biotech Stocks That Could Double Soon
2021-07-21 06:44

Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.

GlobeNewsWire
Neutral
Allakos Completes Patient Enrollment in Phase 3 Eosinophilic Gastritis and/or Eosinophilic Duodenitis and Phase 2/3 Eosinophilic Esophagitis Clinical Trials of Lirentelimab (AK002)
2021-06-07 08:00

-- Results from both clinical trials expected in the fourth quarter of 2021 -- -- CMO Dr. Henrik Rasmussen to retire; Dr. Craig Paterson, SVP of Clinical Development and Medical Affairs, promoted to CMO --

Zacks Investment Research
Negative
Moving Average Crossover Alert: Allakos (ALLK)
2021-06-07 06:46

Allakos (ALLK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Loading more news...